Patent application number | Description | Published |
20150203846 | Treatment of Myelodysplastic Syndrome by Inhibition of NR2F6 - Methods, compositions, and treatment protocols are provided in the current invention for the treatment of myelodysplastic syndrome (MDS) through the inhibition of NR2F6 gene expression or activity of protein. In one embodiment silencing, or substantial inhibition of NR2F6 expression is achieved through induction of RNA interference in cells associated with development of MDS. Induction of differentiation or stimulation of apoptosis as a result of NR2F6 inhibition may be used to reduce the state of MDS, and/or in other embodiments to inhibit or revert progression to leukemic states. | 07-23-2015 |
20150283164 | Treatment of Myelodysplastic Syndrome by Inhibition of NR2F2 - Methods, compositions, and treatment protocols are provided in the current invention for the treatment of myelodysplastic syndrome (MDS) through the inhibition of NR2F2 gene expression or activity of protein. In one embodiment silencing, or substantial inhibition of NR2F2 expression is achieved through induction of RNA interference in cells associated with development of MDS. Induction of differentiation or stimulation of apoptosis as a result of NR2F2 inhibition may be used to reduce the state of MDS, and/or in other embodiments to inhibit or revert progression to leukemic states. | 10-08-2015 |
20150291964 | Methods and Compositions for treatment of cancer by inhibition of NR2F6 - The current invention discloses compositions of matter, protocols and methods of use of treatment for cancer and other diseases of aberrant cellular proliferation and differentiation by inhibiting expression of NR2F6 or activity thereof. In one embodiment, administration of synthetic oligonucleotides that induce RNA interference mediated degradation of the nuclear receptor NR2F6 in human or animal patients is performed at a sufficient concentration or frequency to achieve regression of tumor. | 10-15-2015 |
20150297627 | Methods and Compositions for treatment of cancer by inhibition of NR2F2 - The current invention discloses compositions of matter, protocols and methods of use of treatment for cancer and other diseases of aberrant cellular proliferation and differentiation by inhibiting expression of NR2F2 or activity thereof. In one embodiment, administration of synthetic oligonucleotides that induce RNA interference mediated degradation of the nuclear receptor NR2F2 in human or animal patients is performed at a sufficient concentration or frequency to achieve regression of tumor. | 10-22-2015 |
20150299712 | Modulation of Hematopoietic Stem Cell Differentiation - The invention provides means of manipulating hematopoietic stem cell differentiation by modulation of levels of NR2F6 (EAR2). Provided are compositions of matter, protocols and methods of use by which inhibiting expression of NR2F6 or activity thereof promotes differentiation of selective hematopoietic lineages, or conversely overexpression of NR2F6 or activity thereof inhibits differentiation. In one embodiment inhibition of differentiation is performed in other cell lineages besides hematopoietic. | 10-22-2015 |
20160025746 | METHODS OF SCREENING COMPOUNDS THAT CAN MODULATE NR2F6 BY DISPLACEMENT OF A REFERENCE LIGAND - The current invention discloses compositions of matter, protocols and methods of screening test compounds to identifying agonists and antagonists of the orphan nuclear receptor NR2F6 by measuring the ability of a test compound to occupy the active site of NR2F6, in the presence of a reference compound. | 01-28-2016 |
Patent application number | Description | Published |
20090081245 | ASSAYS FOR DEVELOPMENT OF BORIS MUTANTS SUITABLE FOR VACCINE DEVELOPMENT AND SMALL MOLECULE INHIBITORS OF WILD-TYPE BORIS - Disclosed are methods and compositions for developing mutants of the Brother of the Regulator of Imprinted Sites (BORIS) suitable for immunotherapeutic purposes. Said methods involve the mutagenesis and/or deletion of various sequences within wild-type BORIS protein with the objected aim of constructing nucleic acids and proteins encoded by said nucleic acids capable of eliciting immune responses while concurrently lacking oncogenicity. Methods of screening of small molecule inhibitors of wild-type BORIS activity are also provided. | 03-26-2009 |
20090169613 | TARGETING OF TUMOR STEM CELLS THROUGH SELECTIVE SILENCING OF BORIS EXPRESSION - The present invention provides compositions useful for the treatment of cancer that inhibit tumor stem cells through suppression of an activity or the expression of BORIS. The compositions target tumor stem cells through molecules that are specific to tumor stem cells. Specifically, the invention provides immunoliposomes specific to tumor stem cells that include nucleic acid compositions capable of eliciting the process of RNA interference of BORIS expression. Also provided are immunoliposomes specific to tumor stem cells that include anti-BORIS ribozymes, antisense oligonucleotides, decoy oligonucleotides or small molecule inhibitors. Methods of manufacturing, delivering, and use of such compositions in the treatment of cancer are also provided. | 07-02-2009 |
20090304677 | Extracorporeal Removal of Microvesicular Particles - The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed. | 12-10-2009 |
20100279291 | GENE SILENCING OF THE BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS) - The present invention provides methods and compositions useful for inhibiting expression of the gene encoding the transcription factor, Brother of the Regulatory of Imprinted Sites (BORIS) by RNA interference. Methods of the present invention can be used to silence BORIS in cancer cells, which results in apoptosis and may be useful as for treating cancer in mammals. The methods of the invention directed to cancer therapy can be used alone or in combination with standard cancer treatments such as surgery, radiation, chemotherapy, and immunotherapy. | 11-04-2010 |
20130015118 | EXTRACORPOREAL REMOVAL OF MICROVESICULAR PARTICLES - The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed. | 01-17-2013 |
20130195899 | THERAPEUTIC IMMUNE MODULATION BY STEM CELL SECRETED EXOSOMES - Disclosed are methods, compositions of matter, and protocols useful for the induction of a therapeutic immune modulatory response through administration of exosomes derived from a stem cell source. In one embodiment, said stem cell source is endometrial regenerative cells. Specifically, in one embodiment stem cell derived exosomes are used as a method of treating an autoimmune condition such as rheumatoid arthritis, multiple sclerosis, or systemic lupus erythromatosis. | 08-01-2013 |
20130273011 | STEM CELLS AND STEM CELL GENERATED NANOPARTICLES FOR TREATMENT OF INFLAMMATORY CONDITIONS AND ACUTE RADIATION SYNDROME - Disclosed are stem cells and nanoparticles derived from said stem cells, useful for the treatment of acute radiation syndrome (ARS) and other inflammatory conditions. In one embodiment, Endometrial Regenerative Cells (ERC) are administered to patients having been exposed to radiation to augment recovery of endogenous hematopoietic stem cells. In another embodiment, exosomes, nanoparticles that are generated by various stem cells are used as a drug for treatment of inflammatory conditions. | 10-17-2013 |
20130309210 | ACCELERATION OF HEMATOPOIETIC RECONSTITUTION BY PLACENTAL ENDOTHELIAL AND ENDOTHELIAL PROGENITOR CELLS - Compositions useful for treatment of patients needing hematopoietic stimulation. In one embodiment patients are administered a cellular mixture derived from allogeneic placenta, said cellular mixture comprising substantially of endothelial cells and endothelial progenitor cells. | 11-21-2013 |
20140004087 | ENDOMETRIAL REGENERATIVE CELLS FOR TREATMENT OF TRAUMATIC BRAIN INJURY | 01-02-2014 |
20140065096 | CANCER THERAPY BY EX VIVO ACTIVATED AUTOLOGOUS IMMUNE CELLS - Disclosed are therapeutic methods for ex-vivo activation of immune cells from a cancer patient for the purpose of inducing tumor regression and/or suppressing metastasis and/or tumor recurrence. In one embodiment mononuclear cells of a patient are isolated from peripheral blood and activated by a combination of innate immune system activators together with means allowing for T cell activation. | 03-06-2014 |
20140161810 | EXTRACORPOREAL REMOVAL OF MICROVESICULAR PARTICLES - The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed. | 06-12-2014 |
20140166578 | EXTRACORPOREAL REMOVAL OF MICROVESICULAR PARTICLES - The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed. | 06-19-2014 |
20150037303 | CELLS, COMPOSITIONS, AND TREATMENT METHODS FOR STIMULATION OF HEMATOPOIESIS - The invention discloses novel methods, compositions of matter, and kits for the treatment of disorders affecting the hematopoietic system. Patients are administered an autologous cellular mixture derived from adipose stromal vascular fraction, said cellular mixture comprising endothelial cells, endothelial progenitor cells, T regulatory cells, monocytes, and hematopoietic stem cells. In one embodiment, treatment is provided for patients suffering from inflammatory disorders including aplastic anemia. | 02-05-2015 |
20160074489 | STIMULATION OF IMMUNITY TO TUMOR SPECIFIC AND ENDOTHELIAL SPECIFIC PROTEINS BY IN VIVO DC ATTRACTION AND MATURATION - Treatment of cancer is disclosed through administration of proteins or specific peptides in vivo, in a matter eliciting monocyte or dendritic cell migration in order to allow uptake of said administrated proteins or peptides, followed by administration of a maturation signal in vivo. The invention provides for treatment of cancer through induction of anticancer immunity and/or immunity towards tumor associated blood vessels. | 03-17-2016 |
Patent application number | Description | Published |
20080260703 | Treatment of Insulin Resistance and Diabetes - Disclosed are methods, compositions, and cells useful for increasing insulin sensitivity, as well as lack of insulin production in a host in need thereof. One aspect of the invention discloses methods of increasing skeletal muscle perfusion through administration of cells capable of directly and/or indirectly stimulatory of angiogenesis and/or vascular responsiveness. Another aspect provides means of increasing sensitivity to insulin through administration of a cell composition capable of integrating into host insulin responsive tissue and upregulating responsiveness either through mobilization of host cells capable of responding to insulin, mobilization of host cells capable of endowing insulin responsiveness on other host cells, exogenously administered cells taking the role of insulin responsiveness, or exogenously administered cells endowing insulin responsiveness on other host cells. Another aspect comprises modifying said host to allow for concurrent insulin sensitization and upregulated production of insulin. | 10-23-2008 |
20100247495 | Treatment of Muscular Dystrophy - The present invention provides mesenchymal stem cells and mesenchymal-like cells useful for treatment of muscular dystrophies including Duchenne Muscular Dystrophy (DMD), as well as, Becker, limb girdle, congenital, facioscapulohumeral, myotonic, oculopharyngeal, distal, and Emery-Dreifuss dystrophies. Also provided are protocols for administration of cells for treatment of the above dystrophies and adjuvant protocols. Futhermore, the invention teaches methods of manipulating mesenchymal and mesenchymal-like cells in vitro and in vivo for augmentation of therapeutic effects. Particularly, use of endometrial regenerative cells, alone or in combination with mesenchymal stem cells is provided for treatment of DMD and Becker muscular dystrophy. | 09-30-2010 |
20150299712 | Modulation of Hematopoietic Stem Cell Differentiation - The invention provides means of manipulating hematopoietic stem cell differentiation by modulation of levels of NR2F6 (EAR2). Provided are compositions of matter, protocols and methods of use by which inhibiting expression of NR2F6 or activity thereof promotes differentiation of selective hematopoietic lineages, or conversely overexpression of NR2F6 or activity thereof inhibits differentiation. In one embodiment inhibition of differentiation is performed in other cell lineages besides hematopoietic. | 10-22-2015 |
20160038542 | TREATMENT OF INSULIN RESISTANCE AND DIABETES - Disclosed are methods, compositions, and cells useful for increasing insulin sensitivity, as well as lack of insulin production in a host in need thereof. One aspect of the invention discloses methods of increasing skeletal muscle perfusion through administration of cells capable of directly and/or indirectly stimulatory of angiogenesis and/or vascular responsiveness. Another aspect provides means of increasing sensitivity to insulin through administration of a cell composition capable of integrating into host insulin responsive tissue and upregulating responsiveness either through mobilization of host cells capable of responding to insulin, mobilization of host cells capable of endowing insulin responsiveness on other host cells, exogenously administered cells taking the role of insulin responsiveness, or exogenously administered cells endowing insulin responsiveness on other host cells. Another aspect comprises modifying said host to allow for concurrent insulin sensitization and upregulated production of insulin. | 02-11-2016 |